PPT-Practice Update: Buprenorphine

Claire F Johnson RNBSN PMHNPDNP Student Disclosure I have no actual or potential conflict of interest in relation to this programpresentation Substance misuse is one of the critical public health problems of our time. Jennifer Lofgren, DVM, MS, DACLAM. Unit for Laboratory Animal Medicine. Refinement and Enrichment Application Lab (REAL). University of Michigan Medical School. Rising number of publications indexed on Pubmed with keywords “analgesia” or “pain” and “laboratory animals.”. Kylie Reed . a,b. ,. Karolina . Bogdanowicz. . b, . James Bell . a,b. , . Rob . VanderWaal. . a, . Jenny Keen . a,b. , . Pete . Beavan. . a. , Shelagh Baillie . c, . Alastair Knight . d, . John . Claire Johnson. , RN-BSN, PMHNP-DNP Candidate. Disclosures. I have no actual or potential conflict of interest in relation to this program/presentation.. I believe in treatment and harm reduction strategies for substance use disorders during pregnancy. I agree that drug addiction is a chronic, relapsing brain disease that should receive at minimum adequate treatment during the perinatal time period. Treatment (MAT):. Problem . or Solution?. Quintin Thomas Chipley, M.A., M.D., Ph.D.. a. nd. Greg Jones, M.D., ABFM, ABAM, MRO. Prepared for CAPTASA 2016. DISCLOSURES. Neither presenter has any financial interest in any mode of treatment as discussed in this presentation.. Medication Assisted Treatment and Team Training. in Rural Colorado. Primary Care Practice Training. Copyright 2018 Regents of the University of Colorado.  All Rights Reserved. .. For permission to use content for purposes other than IT MATTTRs Practice Team . Julie Kmiec, DO. Assistant Professor of Psychiatry. University of Pittsburgh. kmiecj@upmc.edu. April 10, 2018. 1. Objectives. Review prevalence of opioid use disorders. Discuss the unmet needs for those with OUD. Therapy. Opioids. and HIV. You may know that…. Injection drug use (IDU), either directly or via sexual contact with an IDU partner, accounts for one-third of the cumulative estimated AIDS cases in the U.S.. Haley Pals, PharmD, BCPP. Tomah VA Medical Center, Tomah WI. ECHO January 6. th. , 2022. Objectives . Recognize the possible routes of training for pharmacists. Identify various established buprenorphine collaborations. Patient Assessmen • Establishment of a diagnosis of Opioid Use Disorder (OUD). • Discussion of current opioid use. • Evaluation of patient’s readiness to participate. • Ph BUPRENORPHINE NALOXONE BNM Sublingual Tablets Buprenorphine Hydrochloride Naloxone Hydrochloride Consumer Medicine Information What is in this leaflet Please read this leaflet carefully before you are Kaylin A . Klie. , MD, MA, FASAM. Addiction Medicine. University of Colorado and Denver Health. ICWB Shared Learning. March 28. th. , 2022. Discussion Today:. Low Dose Buprenorphine Initiation Strategies. Bruce C. Springer, MD, FASAM, ABAM. Mid-State Health Network. OPIATE USE DISORDER. 12.5 million people misused prescription opiates in 2015.. 2.1 million Americans were recently new opiate misusers in 2015. Trish Mashburn, PharmD. April 7th. , . 2022. Course Information. Presentation is sponsored by . the North Carolina Association of Pharmacists (. NCAP). . This live course has been adapted from the following online training module: . Tim Furnish, MD. Clinical Professor. UC San Diego Health. August . 2023. Disclosures. Fellowship Educational Grants: . Medtronic, Abbott, Boston Scientific, Nevro. Buprenorphine. Buprenorphine. FDA Indications, uses, and legal distinctions.